After Leqembi approval, Eisai CEO to retire

Less than a week after Eisai secured a full approval for Leqembi — the first Alzheimer’s drug to achieve full approval — the drugmaker’s CEO announced his plan to retire by the end of July. 

Advertisement

Ivan Cheung, the CEO, president, senior vice president and chair of Eisai, will retire by July 31, according to a July 11 news release. Five executives were promoted, including Tatsuyuki Yasuno, who was CFO and is now acting president of the Americas and CEO and senior vice president of Eisai.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.